gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CLDXHealthcareDiagnostics

Celldex Therapeutics, Inc (CLDX)

$29.93+0.74%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$29.93▲ 25.49% in range
Nov 4, 2025Low $22.58 · High $44.87Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Celldex Therapeutics closed at $29.93 on Nov 4, up 0.74%, 33.3% below its 52-week closing high. Volume of 912.3K shares was 0.76× its 20-day average (below normal).

Split-adjusted performance: -3.5% over one month, -13.0% over six months, +20.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $22K, down 97.0% from a year earlier, with a net margin of -334104.5%.

Short interest was 9.6M shares at the Oct 15 settlement, down 12.8% from the prior report (13.0% of float, 5.9 days to cover).

Market cap$2.35B78.5M shares
Revenue · quarter$22.0K−97.0% YoY
Diluted EPS$-0.94—
P/E · TTM—P/S 14,875.9×
Net margin-334,104.5%Gross 100.0%
Dividend yieldNone
52-week range22.58 – 44.87−33.3% from high
Volume912.3K0.76× 20-day avg
Volatility · 60d47.7%Annualised
Short % of float13.0%5.9 days to cover
Net cash$717.6MCash $717.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.9%1M −3.5%3M −28.0%6M −13.0%YTD +10.2%1Y +20.9%3Y +31.9%5Y −32.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum29
Revenue growth0
Net margin0
Value (low P/E)—
Size79

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short9.6M−12.8% vs prior
Days to cover5.9Settled Oct 15
% of float13.0%
Short vol. 10d62.1%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CLDXCelldex Therapeutics$29.93+0.74%−13.0%−97.0%−334104.5%—$2.35B
NEOGNeogen$12.46+2.98%+35.7%+6.5%−5.3%—$2.72BCompare
NTLAIntellia Therapeutics$12.31+3.79%−11.1%−46.2%−1392.3%—$1.72BCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
LNTHLantheus Holdings$101.14+0.34%+17.4%+2.7%19.3%24.0$6.60BCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare
IDXXIdexx Laboratories$698.55+3.94%+20.6%+9.9%26.1%46.6$55.03BCompare

News about Celldex Therapeutics

All news →
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteZacks Investment Research · Sep 23, 2026NeutralCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswire Inc. · Jun 14, 2026▲ PositiveCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswire Inc. · Jun 14, 2026▲ PositiveCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire Inc. · Apr 6, 2026▲ PositiveCelldex Announces Pricing of $300 Million Public Offering of Common StockGlobeNewswire Inc. · Apr 2, 2026▲ Positive

Quick answers

What does Celldex Therapeutics do?
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases.
What is CLDX's market cap?
$2.35B, based on the Nov 4 close of $29.93.
Does Celldex Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CLDX is sold short?
9.6M shares, 13.0% of float, as of Oct 15, 2026.
What sector is CLDX in?
Healthcare, in the Diagnostics industry.

About Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

HQ: Hampton, NJ198 employeesListed May 15, 1986celldex.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology